| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Issuance costs paid setting up atm agreement | - | 0 |
| Payment for fractional shares in reverse stock split | -367 | 0 |
| Net cash provided by financing activities | 7,930,919 | 7,943,907 |
| Net increase (decrease) in cash and cash equivalents | 1,502,557 | 3,319,360 |
| Cash and cash equivalents at beginning of period | 3,161,570 | - |
| Cash and cash equivalents at end of period | 4,664,127 | - |
Dermata Therapeutics, Inc. (DRMAW)
Dermata Therapeutics, Inc. (DRMAW)